Established and Novel Approaches for the Management of Hyposalivation and Xerostomia

被引:26
作者
Wolff, Andy [1 ]
Fox, Philip C. [2 ]
Porter, Stephen [3 ]
Konttinen, Yrjo T. [4 ,5 ]
机构
[1] Saliwell Ltd, Harutzim, Israel
[2] PC Fox Consulting LLC, Spello, Italy
[3] UCL Eastman Dent Inst, London, England
[4] ORTON Orthopead Hosp, Biomedicum 1, Dept Med, Inst Clin Med, Helsinki, Finland
[5] COXA Hosp Joint Replacement, Tampere, Finland
关键词
Hyposalivation; xerostomia; dry mouth; mouthwashes; pilocarpine; cevimeline; acupuncture; electrostimulation; PRIMARY SJOGRENS-SYNDROME; ADENOVIRAL-MEDIATED TRANSFER; SALIVARY-GLAND HYPOFUNCTION; INCREASED FLUID SECRETION; NECK-CANCER-PATIENTS; DRY EYE SYMPTOMS; DOUBLE-BLIND; CLINICAL-TRIAL; RADIATION-THERAPY; ORAL PILOCARPINE;
D O I
10.2174/138161212803307509
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Hyposalivation, often symptomatically manifested as xerostomia (dry mouth sensation) may indicate the presence of altered salivary gland function and places patients at a higher risk for oral complications. Diverse symptoms and consequences have been associated with hyposalivation, such as difficulties with speaking, swallowing and tasting and a significant increase in dental caries and other oral infections. Although hyposalivation may be caused by a variety of conditions (head and neck radiotherapy, Sjogren's syndrome, medications, etc.), its hallmark symptom, xerostomia, is common to all such disorders, and varies only in intensity. Therefore, treatment is generally non-specific, and similar therapeutic approaches are used in all cases. In the present paper, available palliative oral care in the form of saliva substitutes, such as mouthwashes or gels, is detailed. Also salivary flow stimulants, such as certain pharmaceutical or gustatory preparations, acupuncture and electrostimulation are reviewed. Finally, other approaches, currently under investigation, such as biological and gene therapies, are discussed. The degree of evidence of the best known methods and their intended use are analyzed.
引用
收藏
页码:5515 / 5521
页数:7
相关论文
共 72 条
[1]  
Alajbeg I, 2012, ORAL SURG O IN PRESS
[2]   Saliva - the defender of the oral cavity [J].
Amerongen, AVN ;
Veerman, ECI .
ORAL DISEASES, 2002, 8 (01) :12-22
[3]  
Andersson G, 1995, Gerodontology, V12, P12, DOI 10.1111/j.1741-2358.1995.tb00124.x
[4]   Development of a gene transfer-based treatment for radiation-induced salivary hypofunction [J].
Baum, Bruce J. ;
Zheng, Changyu ;
Alevizos, Ilias ;
Cotrim, Ana P. ;
Liu, Shuying ;
McCullagh, Linda ;
Goldsmith, Corinne M. ;
McDermott, Nancy ;
Chiorini, John A. ;
Nikolov, Nikolay P. ;
Illei, Gabor G. .
ORAL ONCOLOGY, 2010, 46 (01) :4-8
[5]   The management of xerostomia in patients on haemodialysis: comparison of artificial saliva and chewing gum [J].
Bots, CP ;
Brand, HS ;
Veerman, ECI ;
Valentijn-Benz, M ;
Van Amerongen, BM ;
Amerongen, AVN ;
Valentijn, RM ;
Vos, PI ;
Bijlsma, JA ;
Bezemer, PD ;
ter Wee, PM .
PALLIATIVE MEDICINE, 2005, 19 (03) :202-207
[6]  
Brennan Michael T, 2002, Dent Clin North Am, V46, P847, DOI 10.1016/S0011-8532(02)00023-X
[7]   Open-label, long-term safety study of cevimeline in the treatment of postirradiation xerostomia [J].
Chambers, Mark S. ;
Jones, Christopher Uwe ;
Biel, Merrill A. ;
Weber, Randal S. ;
Hodge, Kenneth M. ;
Chen, Y. ;
Holland, John M. ;
Ship, Jonathan A. ;
Vitti, Robert ;
Armstrong, Ingrid ;
Garden, Adam S. ;
Haddad, Robert .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2007, 69 (05) :1369-1376
[8]  
Chitra S, 2008, Indian J Dent Res, V19, P213
[9]   Treatment of primary Sjogren's syndrome with low-dose human interferon alfa administered by the oromucosal route: Combined phase III results [J].
Cummins, MJ ;
Papas, A ;
Kammer, GM ;
Fox, PC .
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH, 2003, 49 (04) :585-593
[10]  
Dawidson I, 1999, THESIS KAROLINSKA I